Literature DB >> 12756417

Immune responses to adeno-associated virus and its recombinant vectors.

J Y Sun1, V Anand-Jawa, S Chatterjee, K K Wong.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors have emerged as highly promising for use in gene transfer for a variety of reasons, including lack of pathogenicity and wide host range. In addition, all virus-encoded genes have been removed from standard rAAV vectors, resulting in their comparatively low intrinsic immunogenicity. For gene replacement strategies, transgenes encoded by rAAV vectors may induce less robust host immune responses than other vectors in vivo. However, under appropriate conditions, host immune responses can be generated against rAAV-encoded transgenes, raising the potential for their use in vaccine development. In this review, we summarize current understanding of the generation of both undesirable and beneficial host immune responses directed against rAAV and encoded transgenes, and how they might be exploited for optimal use of this promising vector system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756417     DOI: 10.1038/sj.gt.3302039

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  46 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 2.  Gene therapy for type 1 diabetes: is it ready for the clinic?

Authors:  Antonella D'Anneo; Pleunie Rood; Rita Bottino; A N Balamurugan; Jing He; Nick Giannoukakis
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

4.  RNA interference with special reference to combating viruses of crustacea.

Authors:  Kathy La Fauce; Leigh Owens
Journal:  Indian J Virol       Date:  2012-08-14

Review 5.  Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.

Authors:  Ling Li; Shuo Hu; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2018-04-18       Impact factor: 12.479

6.  Expression of plasmid DNA in the salivary gland epithelium: novel approaches to study dynamic cellular processes in live animals.

Authors:  Monika Sramkova; Andrius Masedunskas; Laura Parente; Alfredo Molinolo; Roberto Weigert
Journal:  Am J Physiol Cell Physiol       Date:  2009-09-30       Impact factor: 4.249

7.  Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells.

Authors:  Adarsha Koirala; Rasha S Makkia; Mark J Cooper; Muna I Naash
Journal:  Biomaterials       Date:  2011-09-01       Impact factor: 12.479

8.  Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy.

Authors:  Victoria M Velazquez; David G Bowen; Christopher M Walker
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

9.  Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.

Authors:  William M Siders; Jacqueline Shields; Johanne Kaplan; Michael Lukason; Lisa Woodworth; Sam Wadsworth; Abraham Scaria
Journal:  Hum Gene Ther       Date:  2009-01       Impact factor: 5.695

10.  Cationic nano-copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Tenon's capsule fibroblasts in vitro.

Authors:  Yongheng Duan; Xipeng Guan; Jian Ge; Daping Quan; Yehong Zhuo; Hehua Ye; Tingting Shao
Journal:  Mol Vis       Date:  2008-12-31       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.